With 2.49 million shares changed hands, the volume of the stock remained lighter than its average volume of 4.76 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $1.63 whereas the lowest price it dropped to was $1.48. The 52-week range on TNYA shows that it touched its highest point at $7.01 and its lowest point at $0.99 during that stretch. It currently has a 1-year price target of $19.14. Beta for the stock currently stands at 2.91.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of TNYA was up-trending over the past week, with a rise of 2.76%, but this was down by -55.12% over a month. Three-month performance dropped to -15.82% while six-month performance fell -50.33%. The stock lost -49.83% in the past year, while it has gained 4.20% so far this year. A look at the trailing 12-month EPS for TNYA yields -1.48 with Next year EPS estimates of -1.25. For the next quarter, that number is -0.31. This implies an EPS growth rate of 19.60% for this year and 7.81% for next year.
Float and Shares Shorts:
At present, 79.22 million TNYA shares are outstanding with a float of 65.64 million shares on hand for trading. On 2024-12-13, short shares totaled 16.69 million, which was 2106.9999 higher than short shares on 1731628800. In addition to Mr. Faraz Ali M.B.A. as the firm’s CEO, Interim Principal Financial Officer & Director, Dr. Deepak Srivastava M.D. serves as its Scientific Founder, Chairman of Scientific Advisory Board & Director.
Institutional Ownership:
Through their ownership of 0.73807 of TNYA’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, TNYA reported revenue of $0.0 and operating income of -$26711000.0. The EBITDA in the recently reported quarter was -$24610000.0 and diluted EPS was -$0.3.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for TNYA since 3 analysts follow the stock currently. There are 3 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With TNYA analysts setting a high price target of 40.0 and a low target of 6.0, the average target price over the next 12 months is 18.5. Based on these targets, TNYA could surge 2584.56% to reach the target high and rise by 302.68% to reach the target low. Reaching the average price target will result in a growth of 1141.61% from current levels.
Analysts have provided yearly estimates in a range of -$1.29119 being high and -$1.39129 being low. For TNYA, this leads to a yearly average estimate of -$1.35125.
